Single photon emission computed tomography and positron emission tomography in cancer imaging
- 15 February 1991
- Vol. 67 (S4) , 1261-1270
- https://doi.org/10.1002/1097-0142(19910215)67:4+<1261::aid-cncr2820671524>3.0.co;2-l
Abstract
Single photon emission computed tomography (SPECT) and positron emission tomography (PET) are now being used to improve the information available from radioisotopic imaging of patients with cancer. These nuclear medicine techniques offer the potential for studying regional function and biochemistry by using radiolabeled substrates. The chemical changes of malignancy precede anatomic changes, and PET and/or SPECT may detect these changes before anatomic changes have occurred. The superiority of SPECT compared with planar imaging has been demonstrated for cardiac and brain imaging. Radiopharmaceuticals containing technetium 99 m (99mTc) are best suited for SPECT imaging because large amounts of radioactivity are administered and the collimator-camera systems are optimized for the 140 keV photons of 99mTc. The current interest in imaging cancer with SPECT relates to the use of gallium 67 citrate and monoclonal antibodies labeled with iodine 123 or indium 111. SPECT can image these radioisotopes, but the advantages compared with planar imaging have not been clearly defined. Furthermore, the ability to quantitate the distribution of single photon emitters other than 99mTc has not been demonstrated. New SPECT systems with three heads or rings of detectors offer promise for improved, quantitative imaging. PET has the capability of imaging tracers with the biologically important elements C-11, N-13, O-15, and F-18 used for positron labeling. These radioisotopes have short half-lives and require a cyclotron close to the PET facility. The most prominently used radiopharmaceutical for PET is F-18 fluorodeoxyglucose (FDG). PET studies with FDG in patients with primary brain tumors have demonstrated the ability to determine the degree of malignancy, to differentiate necrosis from recurrent tumor after radiation therapy or chemotherapy, and to predict prognosis. Other metabolic functions of cancer have been studied, including amino acid accumulation, thymidine uptake, oxygen utilization, intermediary metabolism, and receptor status. PET has the potential to make a major impact on the characterization of a malignancy and the effect of therapy.Keywords
This publication has 21 references indexed in Scilit:
- Imaging of colorectal carcinoma with radiolabeled antibodiesSeminars in Nuclear Medicine, 1989
- PET of malignant cerebral tumors after interstitial brachytherapyJournal of Neurosurgery, 1988
- The Value of SPECT Imaging in the Diagnosis of Hepatic HemangiomaClinical Nuclear Medicine, 1988
- Positron emission tomography in patients with glioma a predictor of prognosisCancer, 1988
- Rapid Decrease in Amino Acid Metabolism in Prolactin-Secreting Pituitary Adenomas After Bromocriptine TreatmentJournal of Computer Assisted Tomography, 1987
- SPECT instrumentation: Performance, lesion detection, and recent innovationsSeminars in Nuclear Medicine, 1987
- Positron Emission Tomography Using [18F] Fluorodeoxyglucose in Brain Tumors A Powerful Diagnostic and Prognostic ToolInvestigative Radiology, 1987
- Single Photon Emission Computed Tomography (SPECT) Principles and InstrumentationInvestigative Radiology, 1985
- Tomoscintigraphy for detecting gastrointestinal and medullary thyroid cancers: first clinical results using radiolabelled monoclonal antibodies against carcinoembryonic antigen.BMJ, 1982
- Use of Radiolabeled Antibodies to Carcinoembryonic Antigen for the Detection and Localization of Diverse Cancers by External PhotoscanningNew England Journal of Medicine, 1978